{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:28:48Z","timestamp":1786980528780,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Masaryk Memorial Cancer Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Gastroesophageal cancer presents variably across different age groups, with early-onset (EO) cases showing distinct pathological and clinical characteristics compared to late-onset (LO) disease. This study aims to delineate these differences and assess treatment outcomes in a Central European population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from patients diagnosed with gastroesophageal carcinoma and treated between 2010 and 2022, at a high-volume comprehensive cancer center representing approximately 5% of all national gastroesophageal cancer cases in the Czech Republic, were retrospectively analyzed. Patients were categorized into EO (&lt;\u200950 years) and LO (\u2265\u200950 years) groups. Clinicopathological characteristics were compared in the entire cohort, while treatment patterns and survival outcomes were evaluated in patients with adenocarcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 1,377 patients were included, with 161 (11.7%) classified as EO. EO patients are more frequently present with ECOG performance status 0 (42%), lower BMI, current smoking (44%), gastric cancer primaries (63%), and aggressive tumor characteristics such as poorly cohesive adenocarcinoma subtype (45%) and metastatic disease (55%). Hereditary cancer syndrome was confirmed in 4.3% of EO cases. Among adenocarcinoma patients, triplet chemotherapy was more frequently used in the EO group (29% vs. 11%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) in the first-line setting. However, no significant survival benefit was observed in inoperable or metastatic disease (median overall survival 9.1 vs. 9.6 months in EO and LO, respectively,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.913).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>EO gastroesophageal cancer in the Central European population is associated with distinct clinicopathological characteristics, with no significant impact on survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Miniabstract<\/jats:title>\n                    <jats:p>This study identifies distinct clinicopathological characteristics in early-onset gastroesophageal cancer in Central Europe, characterized by more aggressive attributes but without significant survival differences compared to late-onset cases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10120-026-01724-z","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T10:28:42Z","timestamp":1774607322000},"page":"494-505","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Early- versus late-onset gastroesophageal cancer: real-world outcomes from a 13-year central European cohort study"],"prefix":"10.1007","volume":"29","author":[{"given":"Tomas","family":"Sokop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iveta","family":"Selingerova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaclav","family":"Jedlicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lumir","family":"Kunovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7363-7879","authenticated-orcid":false,"given":"Radka","family":"Lordick Obermannova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"1724_CR1","unstructured":"Alvarez EM, Force LM, Xu R et al. The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the global burden of disease study 2019. Lancet Oncol [Internet]. 2022 [cited 2024 Jan 23];23(1):27\u201352."},{"key":"1724_CR2","doi-asserted-by":"crossref","unstructured":"Bergquist JR, Leiting JL, Habermann EB et al. Early-onset gastric cancer is a distinct disease with worrisome trends and oncogenic features. Surg. 2019;166(4):547\u201355.","DOI":"10.1016\/j.surg.2019.04.036"},{"key":"1724_CR3","unstructured":"Du\u0161ek L, Mu\u017e\u00edk J, Kub\u00e1sek M et al. Epidemiologie zhoubn\u00fdch n\u00e1dor\u016f v \u010cesk\u00e9 republice [Internet]. Epidemiol. Zhoub. N\u00e1dor\u016f V \u010ces. Republice. Available from: https:\/\/www.svod.cz\/"},{"issue":"6","key":"1724_CR4","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin [Internet]"},{"issue":"1","key":"1724_CR5","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1158\/1055-9965.EPI-20-0944","volume":"30","author":"DC Codipilly","year":"2021","unstructured":"Codipilly DC, Sawas T, Dhaliwal L, et al. Epidemiology and outcomes of Young-Onset esophageal adenocarcinoma: an analysis from a Population-Based database. Cancer Epidemiol Biomarkers Prev. 2021;30(1):142\u20139.","journal-title":"Cancer Epidemiol Biomarkers Prev [Internet]"},{"key":"1724_CR6","doi-asserted-by":"crossref","unstructured":"Lumish MA, Walch H, Maron SB et al. Clinical and molecular characteristics of early-onset vs average-onset esophagogastric cancer. JNCI J Natl Cancer Inst. 2024;116(2):299\u2013308.","DOI":"10.1093\/jnci\/djad186"},{"key":"1724_CR7","doi-asserted-by":"publisher","first-page":"102344","DOI":"10.1016\/j.coph.2022.102344","volume":"68","author":"A Petrillo","year":"2023","unstructured":"Petrillo A, Federico P, Marte G, et al. Non-hereditary early onset gastric cancer: an unmet medical need. Curr Opin Pharmacol. 2023;68:102344.","journal-title":"Curr Opin Pharmacol [Internet]"},{"key":"1724_CR8","doi-asserted-by":"publisher","first-page":"674224","DOI":"10.3389\/fonc.2021.674224","volume":"11","author":"Q Huang","year":"2021","unstructured":"Huang Q, Zheng X, Jiao Y, et al. A distinct clinicopathological feature and prognosis of young gastric cancer patients Aged\u2009\u2264\u200945 years old. Front Oncol . 2021;11:674224.","journal-title":"Front Oncol [Internet]"},{"issue":"23","key":"1724_CR9","doi-asserted-by":"publisher","first-page":"5927","DOI":"10.3390\/cancers14235927","volume":"14","author":"M Kist","year":"2022","unstructured":"Kist M, Thomaschewski M, Keck Y, et al. Specifics of young gastric cancer patients: A Population-Based analysis of 46,110 patients with gastric cancer from the German clinical cancer registry group. Cancers. 2022;14(23):5927.","journal-title":"Cancers [Internet]"},{"key":"1724_CR10","doi-asserted-by":"crossref","unstructured":"Alberghina L, Piccialli G. From computational genomics to systems metabolomics for precision cancer medicine and drug discovery. Pharmacol Res. 2019;104479.","DOI":"10.1016\/j.phrs.2019.104479"},{"issue":"10","key":"1724_CR11","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/s41571-022-00672-8","volume":"19","author":"T Ugai","year":"2022","unstructured":"Ugai T, Sasamoto N, Lee H-Y, et al. Is early-onset cancer an emerging global epidemic? Current evidence and future implications. Nat Rev Clin Oncol. 2022;19(10):656\u201373.","journal-title":"Nat Rev Clin Oncol [Internet]"},{"issue":"3","key":"1724_CR12","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1158\/2159-8290.CD-22-1038","volume":"13","author":"I Ben-Aharon","year":"2023","unstructured":"Ben-Aharon I, Van Laarhoven HWM, Fontana E, et al. Early-Onset cancer in the Gastrointestinal tract is on the Rise\u2014Evidence and implications. Cancer Discov. 2023;13(3):538\u201351.","journal-title":"Cancer Discov [Internet]"},{"key":"1724_CR13","unstructured":"Mountzios G, Douillard J-Y. Adolescents and young adults with cancer: the pathway of Care. ESMO handb cancer Adolesc young adults. ESMO; 2022."},{"issue":"15","key":"1724_CR14","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.3390\/cancers14153633","volume":"14","author":"M LaPelusa","year":"2022","unstructured":"LaPelusa M, Shen C, Gillaspie EA, et al. Variation in treatment patterns of patients with Early-Onset gastric cancer. Cancers. 2022;14(15):3633.","journal-title":"Cancers"},{"key":"1724_CR15","unstructured":"Qu X, Zhao X, Liu Y et al. The clinicopathological characteristics of early-onset gastric cancer and its evolutionary trends: a retrospective study."},{"key":"1724_CR16","doi-asserted-by":"crossref","unstructured":"Zhou Q-P, Ge Y-H, Liu C-Y. Comparison of metastasis between early-onset and late-onset gastric signet ring cell carcinoma. BMC Gastroenterol. 2020;20(1):380.","DOI":"10.1186\/s12876-020-01529-z"},{"issue":"2","key":"1724_CR17","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/his.13975","volume":"76","author":"ID Nagtegaal","year":"2020","unstructured":"Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182\u20138.","journal-title":"Histopathology [Internet]"},{"key":"1724_CR18","doi-asserted-by":"crossref","unstructured":"Saini KS, Twelves C. Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework. Br J Cancer. 2021;125(2):155\u201363.","DOI":"10.1038\/s41416-021-01319-8"},{"issue":"6","key":"1724_CR19","first-page":"e1","volume":"15","author":"Y Li","year":"2024","unstructured":"Li Y, Hahn AI, Laszkowska M, et al. Clinicopathological characteristics and risk factors of Young-Onset gastric carcinoma: A systematic review and Meta-analysis. Clin Transl Gastroenterol. 2024;15(6):e1.","journal-title":"Clin Transl Gastroenterol [Internet]"},{"issue":"1","key":"1724_CR20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13046-023-02622-3","volume":"42","author":"HJ Lim","year":"2023","unstructured":"Lim HJ, Zhuang L, Fitzgerald RC. Current advances in Understanding the molecular profile of hereditary diffuse gastric cancer and its clinical implications. J Exp Clin Cancer Res. 2023;42(1):57.","journal-title":"J Exp Clin Cancer Res [Internet]"},{"key":"1724_CR21","doi-asserted-by":"crossref","unstructured":"Foretova L, Navratilova M, Svoboda M et al. GAPPS \u2013 Gastric adenocarcinoma and proximal polyposis of the stomach syndrome in 8 families tested at Masaryk memorial cancer Institute \u2013 Prevention and prophylactic gastrectomies. Klin Onkol. 2019;32 (2).","DOI":"10.14735\/amko2019S109"},{"issue":"5","key":"1724_CR22","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00428-019-02541-9","volume":"474","author":"G Baretton","year":"2019","unstructured":"On behalf of the Nicht-interventionelle Untersuchung (NIU) HER2 Study Group, Baretton G, Kreipe HH, et al. HER2 testing in gastric cancer diagnosis: insights on variables influencing HER2-positivity from a large, multicenter, observational study in Germany. Virchows Arch. 2019;474(5):551\u201360.","journal-title":"Virchows Arch [Internet]"},{"key":"1724_CR23","doi-asserted-by":"publisher","first-page":"1272175","DOI":"10.3389\/fonc.2023.1272175","volume":"13","author":"J Tintelnot","year":"2023","unstructured":"Tintelnot J, Stein A, Al-Batran S-E, et al. Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma\u2014a phase II trial of the AIO study group (AIO STO 0321). Front Oncol. 2023;13:1272175.","journal-title":"Front Oncol [Internet]"},{"issue":"16suppl","key":"1724_CR24","doi-asserted-by":"publisher","first-page":"4057","DOI":"10.1200\/JCO.2023.41.16_suppl.4057","volume":"41","author":"AD Wagner","year":"2023","unstructured":"Wagner AD, Grabsch HI, Mauer M, et al. Integration of trastuzumab (T), with or without Pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive gastric (GC) and esophagogastric junction cancer (EGJC): first results of the EORTC 1203 INNOVATION study, in collaboration with the Korean cancer study Group, and the Dutch upper GI cancer group. J Clin Oncol. 2023;41(16):4057\u20134057.","journal-title":"J Clin Oncol [Internet]"},{"key":"1724_CR25","doi-asserted-by":"crossref","unstructured":"Cunningham D, Allum WH, Stenning SP et al. Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. N Engl J Med. 2006;355(1):11\u201320.","DOI":"10.1056\/NEJMoa055531"},{"issue":"2","key":"1724_CR26","doi-asserted-by":"publisher","first-page":"104134","DOI":"10.1016\/j.esmoop.2025.104134","volume":"10","author":"RL Obermannov\u00e1","year":"2025","unstructured":"Obermannov\u00e1 RL, Leong T. ESMO clinical practice guideline interim update on the treatment of locally advanced oesophageal and oesophagogastric junction adenocarcinoma and metastatic squamous-cell carcinoma. ESMO Open. 2025;10(2):104134.","journal-title":"ESMO Open [Internet]"},{"key":"1724_CR27","doi-asserted-by":"crossref","unstructured":"Lordick F, Carneiro F, Cascinu S et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005\u20131020.","DOI":"10.1016\/j.annonc.2022.07.004"},{"key":"1724_CR28","unstructured":"Lordick F, Candia Montero L, Castelo-Branco L et al. ESMO Gastric Cancer Living Guideline, v. 1.4. 2024. Available from: https:\/\/www.esmo.org\/living-guidelines\/esmo-gastric-cancer-living-guideline"},{"issue":"1","key":"1724_CR29","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s10120-023-01443-9","volume":"27","author":"P P\u00e9rez-Wert","year":"2024","unstructured":"P\u00e9rez-Wert P, Custodio A, Jimenez-Fonseca P, et al. Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry. Gastric Cancer. 2024;27(1):131\u201345.","journal-title":"Gastric Cancer [Internet]"},{"key":"1724_CR30","doi-asserted-by":"crossref","unstructured":"Nakayama I, Chin K, Takahari D et al. Treatment features of systemic chemotherapy in young adults with unresectable advanced or recurrent gastric cancer. Cancer Manag Res. 2018;Volume 10:5283\u20135290.","DOI":"10.2147\/CMAR.S179219"},{"key":"1724_CR31","doi-asserted-by":"crossref","unstructured":"Zaanan A, Bouch\u00e9 O, De La Fouchardi\u00e8re C et al. TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2025;S1470204525001305.","DOI":"10.1016\/S1470-2045(25)00130-5"},{"issue":"6","key":"1724_CR32","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1001\/jamaoncol.2021.0848","volume":"7","author":"PS Hall","year":"2021","unstructured":"Hall PS, Swinson D, Cairns DA, et al. Efficacy of Reduced-Intensity chemotherapy with oxaliplatin and capecitabine on quality of life and cancer control among older and frail patients with advanced gastroesophageal cancer: the GO2 phase 3 randomized clinical trial. JAMA Oncol. 2021;7(6):869.","journal-title":"JAMA Oncol [Internet]"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-026-01724-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-026-01724-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-026-01724-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:59:50Z","timestamp":1781643590000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-026-01724-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1724"],"URL":"https:\/\/doi.org\/10.1007\/s10120-026-01724-z","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no conflicts of interest regarding the publication of this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Institutional Ethical Committee of MMCI (approval No. 2024\/179\/MOU), and all participants provided informed consent for the use of their data for research purposes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal participants"}}]}}